The genetic determinants involved in reduced susceptibility to third-generation cephalosporins and aztreonam were identified in ten canine Enterobacter isolates associated with opportunistic infections in three veterinary hospitals in Brisbane, Australia. All isolates were evaluated by a combination of phenotypic (broth microdilution and disc susceptibility, modified disc diffusion and IEF) and genotypic (PFGE, plasmid analysis, Southern blot hybridization, bacterial conjugation, PCR and sequencing) methods to investigate genetic relatedness and to identify plasmid-mediated resistance genes, in particular b-lactamase genes responsible for extended-spectrum cephalosporin resistance. The ten canine isolates were genotypically diverse based on PFGE and belonged to either Enterobacter cloacae or Enterobacter hormaechei on the basis of 16S rRNA gene sequence analysis. Plasmid profiles were also diverse. Nine isolates contained a transmissible bla SHV-12 -carrying plasmid (~140 kb) that also conferred resistance to chloramphenicol, gentamicin, spectinomycin, tetracycline, trimethoprim and sulfonamides. In all plasmid-mediated extended-spectrum b-lactamase (ESBL)-producing isolates including transconjugants, bla SHV-12 was shown to reside in a~6.5 kb plasmid fragment. The remaining isolate that was not an ESBL producer possessed an AmpC b-lactamase gene (bla CMY-2 ) on ã 93 kb transmissible plasmid. This plasmid did not contain any other antimicrobial resistance genes. Additional plasmid-mediated b-lactamases identified in some isolates included bla TEM and bla . This is the first report of canine Enterobacter isolates containing transmissible plasmid-mediated bla SHV-12 and bla CMY-2 resistance genes. Therefore, Enterobacter isolated from opportunistic infections in dogs may be an important reservoir of plasmid-mediated resistance genes, which could potentially be spread to other members of the Enterobacteriaceae.
INTRODUCTION
In humans, Enterobacter spp. and especially Enterobacter cloacae have been reported to be the most frequent cause of neonatal sepsis, with most infections being nosocomial in origin (Fernández-Baca et al., 2001; Liu et al., 2004) . Originally, resistance of Enterobacter spp. to expandedspectrum cephalosporins was shown to be mediated by derepressed mutants that overproduced the chromosomal AmpC b-lactamase (Seeberg et al., 1983; Hanson & Sanders, 1999) . In the last decade, there has been an increase in the reported incidence of plasmid-mediated extendedspectrum b-lactamases (ESBLs) in Enterobacter spp. Infections caused by ESBL-producing Enterobacter cloacae have become a serious clinical problem in many countries such as the USA, Taiwan and Korea (Levison et al., 2002; Lee et al., 2003; Liu et al., 2004; Park et al., 2005) . Alarmingly, ESBL-producing Enterobacter spp. frequently produce multiple b-lactamases, with many recent isolates carrying bla CTX-M in addition to bla TEM and bla SHV (Ho et al., 2005; Ma et al., 2005; Schlesinger et al., 2005) . Moreover, there has been a recent report of bla ESBLs co-existing with quinolone resistance determinants on the same Enterobacter cloacae plasmid (Corkill et al., 2005) .
The Clinical and Laboratory Standards Institute currently recommends ESBL screening and confirmatory testing only in Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca and in some cases Proteus mirabilis. Therefore, comparatively less is known about the incidence of ESBLs in Enterobacter. Detection of ESBLs in Enterobacter spp. can be complicated due to the high-level production of chromosomal AmpC by de-repressed mutants (Thomson et al., 1999) . A study in Greece during 1998 and 1999 showed that ESBL rates of 25 and 58 % were identified in consecutive isolates of Enterobacter cloacae and Enterobacter aerogenes, respectively (Tzelepi et al., 2000) . Similarly, Pai et al. (2004) tested blood isolates of Enterobacter spp. in a Korean tertiary hospital from 1994 to 2001 and reported an overall ESBL prevalence of 43 %. Several reports have identified SHV variants in members of the Enterobacteriaceae such as bla , bla , bla SHV-7 and bla SHV-12 in many countries (Levison et al., 2002; Liu et al., 2004; Chia et al., 2005; Corkill et al., 2005; Schlesinger et al., 2005) . These findings highlight the need to test for ESBL production in Enterobacter spp. in order to determine the spread of these resistance mechanisms. The prevalence of ESBL detection in Enterobacter cloacae isolated in Australia between 1998 and 2001 was 4 % (Bell et al., 2003) . This is a much lower percentage than that found in some Asian countries, in which the percentage of ESBL-producing Enterobacter cloacae was reported to be 19-44 % (Bell et al., 2003) . Resistant Enterobacter spp. also have been reported to cause bacteraemias in Australia (Gottlieb & Wolfson, 2000) , and the cefepime MIC 50 and MIC 90 values of these Enterobacter spp. were alarmingly high (16 and >256 mg cefepime ml 21 , respectively). Recently, K. pneumoniae isolates producing SHV-2a and SHV-12 have been identified in a hospital in Brisbane, Australia (Howard et al., 2002) . To date, the only report of an ESBL detected in isolates from dogs has been the identification of bla in Escherichia coli (Teshager et al., 2000; Carattoli et al., 2005) . In the present study, we examined a collection of multidrugresistant (MDR) canine Enterobacter spp. isolates from Brisbane, Australia, for the production of ESBLs, AmpC and other plasmid-mediated resistance genes. This is the first report of Enterobacter isolates from dogs that produce plasmid-mediated ESBLs and AmpC.
METHODS
Bacterial strains. A collection of ten isolates was evaluated. These were identified provisionally as Enterobacter cloacae and were isolated from clinical opportunistic infections in dogs between 2001 and 2005. All isolates were obtained from clinical swabs or urine specimens submitted to The University of Queensland Veterinary Diagnostic Laboratory (UQVDL). Each isolate was obtained from a single dog. One isolate obtained from a tarsal joint swab of a dog with osteomyelitis following surgical repair of a fracture (Ec1) has been described previously as C10a (Warren et al., 2001; Sidjabat et al., 2006b) . The other nine isolates were obtained from various clinical specimens submitted by three veterinary referral hospitals in Brisbane, Australia (Table 1) . The species assignment of the isolates was confirmed biochemically using the Microbact 24E system (Medvet Diagnostics). On the basis of disc diffusion susceptibility testing, all ten isolates displayed resistance to extended-spectrum cephalosporins and co-amoxiclavulanate.
PCR and sequencing of 16S rRNA genes. DNA was extracted by a heat lysis protocol and the 16S rRNA gene of each isolate was amplified using primers 27f and 1492r (Milinovich et al., 2006) . The conserved primers 27f, 803f, 907r and 1492r were used to determine the sequences. Amplicons were purified using the QIAquick PCR purification kit (Qiagen) according to the manufacturer's instructions. The ABI Prism Big Dye Terminator Cycle Sequencing Ready Reaction kit version 3.1 (Applied Biosystems) was used to sequence PCR amplification products and sequences were obtained using an Applied Biosystems/Hitachi 3130XL Genetic Analyser. Sequencing analyses were performed online using BLAST (www.ncbi.nlm.nih.gov/ BLAST/).
Susceptibility testing and IEF. The MICs of 15 antimicrobials (Table 2) were determined using the CLSI microbroth dilution method (NCCLS, 2002) . The combination of clavulanic acid with either cefotaxime or ceftazidime was determined by Etest (AB Biodisk). Escherichia coli ATCC 25922 and ATCC 35218 were used as reference strains. Phenotypic detection of ESBL production was performed using the modified double-disc test (Pitout et al., 2003) . Isolates that were resistant to third-generation cephalosporins and also resistant to the combination of third-generation cephalosporins with clavulanic acid were suspected to overexpress chromosomal AmpC or possibly produce a plasmid-mediated AmpC. bLactamases were also identified by IEF of sonic extracts of each isolate, as described previously (Sidjabat et al., 2006a) .
PFGE and plasmid analysis. Genomic DNA for PFGE was prepared as described previously (Sidjabat et al., 2006a) and separated using a GeneNavigator system (Pharmacia). Fingerprints were generated by XbaI digestion and electrophoresed using a 5-50 s pulse time and 200 V for 25 h in 0.56 TBE buffer at 12 uC. The genetic relatedness among isolates was interpreted by the number of band differences among the PFGE patterns (Tenover et al., 1995) . Isolates with identical or related PFGE patterns were considered to be derived from a common clone. Plasmids were extracted using the alkaline-lysis method as described previously (Sidjabat et al., 2006a) . Plasmid sizes were estimated by comparison with plasmids of known size from the reference strains Escherichia coli R1 (93 kb) and Escherichia coli R27 (169 kb) and using a BAC Tracker Supercoiled DNA ladder (Epicentre Biotechnologies).
PCR detection and sequence analysis of resistance genes.
Details of the preparation of bacterial lysates, specific primer pairs and PCR conditions for identification of bla TEM , bla SHV and bla OXA genes have been described previously (Vahaboglu et al., 1998; Sidjabat et al., 2006a) . DNA sequencing was performed using the same primers that generated the amplified products. Chloramphenicol resistance genes, integrase and integron cassette resistance genes were detected by PCR and the DNA was sequenced using primers and PCR conditions as described previously (Sidjabat et al., 2006a) . All isolates were subjected to identification of plasmid-mediated AmpC b-lactamase genes by multiplex PCR (Pérez-Pérez & Hanson, 2002) . The primer pair CMY25F1 and CMY2DR1 (Hanson et al., 2002) was used to amplify and sequence the entire structural gene of bla CMY-2 . Long-template amplification of all products for sequence analysis was performed using Platinum Taq DNA Polymerase (Invitrogen), as directed by the manufacturer, and purified using the High Pure PCR Product Purification kit (Roche Diagnostics). Sequencing and sequence analyses were performed as described above. (2) of the ESBL and AmpC genotypes are indicated, as determined by PCR and sequencing using b-lactamase specific primers. DThe presence of plasmid-mediated AmpC b-lactamase genes was determined by multiplex PCR (Pérez-Pérez & Hanson, 2002) . dThe integron gene cassette arrays were fully sequenced. §The previous number of this isolate was C10a (Warren et al., 2001) . Ec7 was suggested to produce AmpC by the CLSI method and an ESBL by the modified disc diffusion method, but was negative in the multiplex AmpC PCR assay. ||Sequencing of the integron consisted of a partial sequence of the aadA2 gene and the sequence of an IS5 transposase Southern blot hybridization analysis. DNA (uncut plasmids and BamHI-digested plasmid) was hybridized to DNA probes generated from PCR products using bla SHV (885 bp) and bla CMY (462 bp) template and a digoxigenin nucleic acid labelling and detection system (Roche Diagnostics).
Conjugation experiments. Conjugation experiments were performed for all isolates using sodium azide-resistant Escherichia coli
J53Az
R as the recipient (Sidjabat et al., 2006a) . Transconjugants were selected on Mueller-Hinton agar supplemented with 120 mg sodium azide ml 21 and 50 mg ampicillin ml
21
. Plasmid transfer from Enterobacter to the Escherichia coli J53Az R transconjugants was confirmed by bla SHV , bla CMY and bla OXA primer-specific PCR, plasmid analysis, Southern blot hybridization and IEF. Transconjugants were confirmed to be Escherichia coli using biochemical tests and species-specific PCR amplification of Escherichia coli uspA (Sidjabat et al., 2006a). 
RESULTS
Species identification, antimicrobial susceptibility profile and phenotypic detection of b-lactamases
All isolates were identified as Enterobacter cloacae on the basis of their biochemical reactions using the Microbact 24E system. PCR and sequencing of the 16S rRNA gene confirmed that each isolate belonged to the genus Enterobacter; however, it was difficult to determine the exact species identity using this method. Alignments of the 16S rRNA gene sequences of Ec1, Ec2, Ec6, Ec8 and Ec9 were identical and produced significant identities (99 %) with both Enterobacter hormaechei and Enterobacter cloacae. However, the 16S rRNA gene sequences of the remaining isolates (Ec3, Ec4, Ec5, Ec7 and Ec10) differed from the above isolates by 5-7 nt. Although these isolates also had approximately 99 % identity with both Enterobacter hormaechei and Enterobacter cloacae, the identity with Enterobacter hormaechei was slightly higher. Because of recent changes in Enterobacter taxonomy and classification, Enterobacter hormaechei is now divided into several subspecies, which together with Enterobacter cloacae and several other Enterobacter species and genovars are combined within the so-called Enterobacter cloacae complex (Hoffmann et al., 2005) .
MIC testing showed that all of the canine Enterobacter spp. isolates were resistant to ampicillin, piperacillin, ticarcillin, gentamicin, spectinomycin, cefoxitin, cefotaxime, ceftazidime and aztreonam ( Table 2 ). The majority of the isolates 
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T -E c 8 E c 8 E c 9 E c 1 0 E c 1 0 were also resistant to enrofloxacin (8/10 isolates), chloramphenicol (8/10 isolates) and sulfamethoxazole/trimethoprim (9/10 isolates). All ten isolates were sensitive to amikacin and imipenem (data not shown).
Nine isolates (Ec1-Ec7, Ec9 and Ec10) were shown to produce an ESBL by the modified double-disc test method. Ec7 and Ec8 showed resistance to ceftazidime and cefotaxime and showed no inhibition to these respective antimicrobials when they were combined with clavulanic acid.
PFGE and plasmid analysis
The PFGE patterns of the ten Enterobacter isolates comprised seven distinct PFGE profiles, designated A-G ( Fig. 1 and Table 1 ). Three isolates had an indistinguishable PFGE pattern (Ec1, Ec2 and Ec6) and therefore were considered to represent the same strain, designated PFGE pattern A. Two isolates (Ec8 and Ec9) were considered to be closely related, as these PFGE patterns differed by only three different bands. The remaining isolates, Ec3-Ec5, Ec7 and Ec10, were shown to be genotypically unrelated to any other strains, as their PFGE patterns differed considerably from the PFGE patterns of other strains (Fig. 1) . All Enterobacter isolates possessed large plasmids, which were larger than or equal to the~93 kb plasmid of Escherichia coli R1 (Fig. 2) . All but two isolates (Ec7 and Ec8) possessed a large~140 kb plasmid, whereas the plasmids from Ec7 and Ec8 werẽ 93 kb in size. Six isolates (Ec4, Ec5, Ec7 and Ec8-Ec10) also had small plasmids (<23 kb). The BamHI-digested plasmid profiles of eight isolates (Ec1-Ec7 and Ec10) were relatively similar, although there were differences in band intensity. The digested plasmid profiles of Ec8 and Ec9 were closely related and differed significantly from the other isolates.
Antimicrobial resistance genes and IEF
Antimicrobial resistance genes identified from sequence analysis of the amplified products are listed in Table 1 . All isolates possessed bla TEM , and in isolates Ec1, Ec2 and Ec3, the sequence alignments were identical with bla TEM-1 , which was in accordance with the identified b-lactamase pI of 5.4. Meanwhile, alignments of the bla SHV nucleotide sequences from all ESBL-producing isolates (Ec1-Ec7, Ec9 and Ec10) were identical with the bla SHV-12 sequence, which correlated with the b-lactamase pI of 8.2. In isolate Ec6, the OXAspecific amplified product was identified as bla OXA-10 and production of this gene product correlated with the blactamase with a pI of~6.3. The ampC multiplex PCR indicated the presence of a Citrobacter-type gene in only one isolate, Ec8. The AmpC gene was amplified from this isolate with primers designed to flank the entire structural gene for either bla CMY-2 or bla CMY-7 (CMY25F1 and CMY2DR1). Sequence analysis of the amplified product from Ec8 was identical to bla CMY-2 (GenBank accession no. X91840); this was in accordance with an identified b-lactamase with a pI of 8.9. In addition, IEF detected bands with a pI of 7.9 in two isolates (Ec3 and Ec10) and a band with a pI of 8.4 in isolate Ec7. These bands may represent Enterobacter chromosomal AmpC, as the bands were not inhibited by clavulanic acid and were not apparent in the transconjugants.
Identification of integrase and integron class 1-specific resistance genes indicated that all ten Enterobacter isolates possessed a class 1 integron-associated streptomycin/ spectinomycin resistance gene (aadA2) ( Table 1) . Interestingly, Ec8, which possessed bla CMY-2 , also carried two class 1 integrons, each containing a single resistance gene (aadA2 and dfrV). In addition, eight of the ten isolates possessed the chloramphenicol resistance gene catA2.
Conjugation and Southern blot hybridization experiments
Only large plasmids were transferred by conjugation (Fig. 2) . The Escherichia coli transconjugants were designated according to their corresponding Enterobacter donor strain, i.e. T-Ec1-T-Ec8 and T-Ec10. The bla SHV-12 -carrying plasmids of eight isolates (Ec1-Ec7 and Ec10), the bla CMY-2 -carrying plasmid of Ec8 and the bla OXA-10 -carrying plasmid of Ec6 were readily transferred into Escherichia coli J53Az R by conjugation. This was confirmed by plasmid analysis, Southern blot hybridization, primer-specific PCR and sequencing of b-lactamase genes possessed by donors and their corresponding tranconjugants. The bla SHV-12 gene was carried on a large~140 kb plasmid, whereas the plasmid carrying bla CMY-2 was~93 kb in size (data not shown). Furthermore, Southern blot hybridization of the BamHIdigested plasmids of the transconjugants with a bla SHV probe confirmed that bla SHV-12 was located on an~6.5 kb plasmid fragment within the~140 kb plasmid common to all Enterobacter strains and their respective transconjugants except Ec8 and Ec9 (data not shown). Hybridization of digested plasmids from Ec8 and T-Ec8 with the bla CMY probe confirmed the location of bla CMY-2 on an~23 kb plasmid fragment within the~93 kb plasmid (data not shown). In addition, bla SHV-12 and bla CMY-2 genes from the transconjugants were sequenced to confirm their identity with the corresponding genes in the donor isolates.
The susceptibility patterns of 17 antimicrobials for the transconjugants were determined (Table 2 ). These data indicated that bla SHV-12 contributed to ceftazidime and aztreonam resistance. Resistance to chloramphenicol, gentamicin, streptomycin, trimethoprim/sulfamethoxazole and spectinomycin was co-transferred by conjugation to all recipients, except in the single isolate producing bla CMY-2 . Transfer of tetracycline resistance was also demonstrated for all bla SHV-12 -producing isolates except Ec4. Resistance to enrofloxacin was not transferable by conjugation for any of the isolates. In addition, the transmissible bla CMY-2 -carrying plasmid in isolate Ec8 did not carry resistance for any of the other antimicrobial agents tested. Even though the susceptibility pattern of Ec8 confirmed that this isolate was resistant to chloramphenicol, gentamicin, spectinomycin, streptomycin, tetracycline and trimethoprim, these resistance phenotypes were not co-transferred by conjugation.
DISCUSSION
This paper describes the first occurrence of an ESBL or AmpC b-lactamase in Enterobacter spp. isolated from dogs. The first Enterobacter case occurred at the same time as a cluster of MDR Escherichia coli (MDREC) nosocomial infections (2000) (2001) in The University of Queensland Veterinary Teaching Hospital (Sidjabat et al., 2006a) . During a 1 year infection control study conducted from mid-2000 to mid-2001, MDR Enterobacter was rarely isolated (1/129 isolates) from rectal swabs of hospitalized dogs compared with MDREC, but was more frequently isolated from swabs of the hospital environment (Sidjabat et al., 2006b) .
PFGE confirmed that the ten canine MDR Enterobacter isolates were clonally diverse, although it was observed that three isolates (Ec1, Ec2 and Ec6) had the same PFGE pattern (A). These three isolates also had similar plasmid profiles and did not possess plasmids smaller than 23 kb. This indicated that the spread of resistant Enterobacter in dogs was largely mediated by horizontal gene transfer of thẽ 140 kb ESBL-containing plasmid to unrelated strains. However, clonal dissemination of PFGE pattern A was confirmed, as it first emerged at The University of Queensland Veterinary Teaching Hospital (Ec1), but was then isolated from a different referral hospital approximately 3 years after the first case (Ec6). Interestingly, analysis of the b-lactamases possessed by strain Ec6 confirmed the recent acquisition of plasmid-mediated OXA-10. Resistance gene acquisition on plasmids may explain the fact that Ec8 and Ec9 are clonally related based on their PFGE patterns (F1 and F2), with Ec9 isolated 9 months after Ec8 from a different infection site in a different dog at the same hospital. Ec8 possessed an~93 kb plasmid containing a single resistance gene (bla CMY-2 ), whereas Ec9 contained the~140 kb bla SHV-12 plasmid. Interestingly, Ec9 was the only isolate for which a transconjugant was not obtained.
Previously, bla SHV-2 was documented as the most prevalent ESBL throughout the world (Paterson et al., 2003) . However, the prevalence of bla SHV-12 in human isolates of members of the Enterobacteriaceae is increasing in many countries (Yan et al., 2000; Lee et al., 2003; Kim et al., 2005) . Similarly, in Australia, bla SHV-2a and bla SHV-12 were found commonly to be present in hospital isolates of K. pneumoniae (Howard et al., 2002) . The presence of a combination of bla SHV-12 and bla TEM in human Enterobacter cloacae isolates has been found in other countries (Chia et al., 2005; Ho et al., 2005; Ma et al., 2005; Schlesinger et al., 2005) , but is yet to be confirmed in human isolates from Australia. In addition, the presence of both bla SHV-12 and aadA2 in Enterobacter cloacae has been reported in isolates identified in Liverpool, UK (Corkill et al., 2005) .
Recently, bla CMY-7 was identified in canine MDREC isolated from dogs in Brisbane (Sidjabat et al., 2006a) . Interestingly, the~93 kb MDREC bla CMY-7 plasmid and the~93 kb bla CMY-2 plasmid in Enterobacter cloacae isolate Ec8 did not confer resistance to other non-b-lactam antibiotics, suggesting that these plasmids could possibly be related. However, the BamHI-digested profiles of the Enterobacter cloacae and MDREC plasmid profiles were distinct (Sidjabat et al., 2006a) . Furthermore, the bla CMY-2 -carrying plasmid in Enterobacter spp. was transferable by conjugation, whilst bla CMY-7 in Escherichia coli was not. The presence of bla CMY-2 in Enterobacter spp. was unusual, as most reports identify the presence of this gene in Escherichia coli, Salmonella sp. and Klebsiella sp., and only one very recent report has confirmed the detection of this b-lactamase gene in an Enterobacter cloacae human isolate from Taiwan (Su et al., 2006) .
There have been very few reports of the occurrence of ESBLs in animal isolates (Teshager et al., 2000; Carattoli et al., 2005) . The increasing prevalence of ESBLs in K. pneumoniae and Escherichia coli isolated from humans is well documented, and the presence of ESBLs in Enterobacter spp. that often cause serious systemic nosocomial infections is now a reality in hospitalized patients worldwide (Liu et al., 2004; Ho et al., 2005) . The inappropriate use and/or overuse of expanded-spectrum b-lactams has been associated with the emergence and spread of ESBL-producing organisms in human hospitals (Bradford, 2001 ). However, use of expanded-spectrum b-lactams is extremely limited in companion animal practice in Australia, whereas the use of b-lactam/clavulanate combinations is widespread (Sidjabat et al., 2006a, b) . However, the presence of multiple resistance mechanisms on the same bla SHV-12 -encoding plasmid would ensure co-selection by a number of commonly used veterinary antimicrobials, such as doxycycline and sulfonamide/trimethoprim.
There have been reports on the treatment failure of infections in humans caused by ESBL-producing bacteria using third-generation cephalosporins, whereas the fourthgeneration cephalosporin cefepime may be of clinical value for the treatment of some infections (Ramphal & Ambrose, 2006) . However, an Australian study confirmed that more than 40 % of Enterobacter spp. isolates from humans were resistant to cefepime. Therefore, treatment using fourthgeneration cephalosporins is also not recommended before the susceptibility testing is known (Gottlieb & Wolfson, 2000) .
The emergence of MDR Enterobacter isolates containing ESBL and AmpC b-lactamases in dogs has not been reported previously, but could theoretically occur by a number of routes and human-to-dog transmission should not be overlooked, especially since the recently documented cases of interspecies transmission of meticillin-resistant Staphylococcus aureus between humans and companion animals (Weese et al., 2006) . The persistence of MDR Enterobacter in the veterinary hospital environment could be a major contributor to the emergence of clinical infections in dogs caused by these strains, as the majority of environmental isolates obtained during an infection control study (Sidjabat et al., 2006b) belonged to PFGE pattern A (H. E. Sidjabat, D. J. Trott & S. M. Moss, unpublished results). The high percentage of canine clinical isolates (90 %) that readily selftransfer their plasmids is a cause for concern and suggests that there is the potential for interspecies spread of bla SHV-12 -and bla CMY-2 -carrying plasmids among members of the Enterobacteriaceae. Therefore, infection control procedures that prevent the spread of resistant bacteria are equally relevant in the veterinary context and should receive strong consideration.
